Anthony Conway, PhD

Founder & CEO

Prior to founding Stem Therapeutics, Dr. Conway was recruited to Replay Holdings to build their Cell Therapy department and strategy, where he successfully led clinical, CMC, and pre-clinical activities and teams as program and alliance manager in partnership with MD Anderson Cancer Center and Miltenyi Biotec. Prior to Replay, Dr. Conway was Project Director at Novo Nordisk’s global R&D headquarters in Denmark where he led 7 pluripotent stem cell-derived cell therapy programs, 4 of which were genome edited hypoimmunogenic allogeneic cell therapies for regenerative medicine. Prior to this, Dr. Conway built Sangamo Therapeutics’ iPSC-derived cell therapy platform and programs which included hypoimmunogenic allogeneic iPSC-CAR-Tregs for autoimmunity and solid organ transplant tolerization and an undisclosed iPSC-derived CAR-NK program. He also led the company’s hypoimmunogenic allogeneic primary CAR-T platform which was subsequently licensed to Kite/Gilead in the field of oncology. Dr. Conway received his PhD in Chemical and Biomolecular Engineering from UC Berkeley, where his focus was on pluripotent stem cell-derived cell therapies for neurodegenerative disorders.